Concepedia

Julie S. Moyers

JS

Statistics

Publications

32

Citations

5.4K

H-Index

24

Active since

1990

Affiliations

Eli Lilly (United States)(Current)

Joslin Diabetes Center

Harvard University

University of Virginia

Profil Institute for Metabolic Research

Julie S. Moyers is an author at Eli Lilly (United States) specializing in cell signaling, life sciences, and diabetes mellitus.

ORCID

Publications per year

1990–2025

32

Publications

32

FGF-21 as a novel metabolic regulator

Alexei Kharitonenkov, Tatiyana L. Shiyanova, Anja Köester et al. · Journal of Clinical Investigation · 2005 · 2.1K citations · Full text

, , +17

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

, , +17

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

Alexei Kharitonenkov, James D. Dunbar, Holly A. Bina et al. · Journal of Cellular Physiology · 2007 · 320 citations

, , +14

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 276 citations · Full text

, , +17

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Ricardo J. Samms, Michael E. Christe, Kyla Collins et al. · Journal of Clinical Investigation · 2021 · 227 citations · Full text

, , +17

1–5 of 32